Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127292262 | 12729226 | 2 | F | 20160826 | 20160909 | 20160909 | 20160915 | EXP | IT-PFIZER INC-2016421948 | PFIZER | 86.00 | YR | M | Y | 0.00000 | 20160915 | MD | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127292262 | 12729226 | 1 | PS | LORAZEPAM. | LORAZEPAM | 1 | Oral | 2.5 MG, TOTAL | Y | 74243 | 2.5 | MG | TABLET | ||||||
| 127292262 | 12729226 | 2 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 125 MG, TREATMENT PERIOD: 3 YEARS | 0 | 125 | MG | TABLET | |||||||
| 127292262 | 12729226 | 3 | C | ENALAPRIL | ENALAPRIL | 1 | Oral | TREATMENT PERIOD: 3 YEARS | 0 | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127292262 | 12729226 | 1 | Anxiety |
| 127292262 | 12729226 | 2 | Cardiac failure |
| 127292262 | 12729226 | 3 | Cardiac failure |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127292262 | 12729226 | Accidental overdose | |
| 127292262 | 12729226 | Ataxia | |
| 127292262 | 12729226 | Sopor |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127292262 | 12729226 | 1 | 20160825 | 20160826 | 0 |